AstraZeneca Competitors and Similar CompaniesClear all
AstraZeneca's competitors and similar companies include Daiichi Sankyo, Boehringer Ingelheim, Sanofi, Novartis, GSK, Amgen, Bayer, Bristol Myers Squibb and Teva Pharmaceuticals.
 AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. |  Daiichi Sankyo Daiichi Sankyo (第一三共株式会社) is a company specializing in the research, development, and manufacture of innovative pharmaceutical products. |  Boehringer Ingelheim Boehringer Ingelheim International is a pharmaceutical company specializing in animal health, human pharma, and biopharmaceutical contract manufacturing. |  Sanofi Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  GSK GSK (GlaxoSmithKline) is a science-led healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. |  Bristol Myers Squibb Bristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products. | |||
Founding Date | Founding Date 1999 | Founding Date 2005 | Founding Date 1958 | Founding Date 1994 | Founding Date 1996 | Founding Date 2000 | Founding Date 1980 | Founding Date 1863 | Founding Date 1887 | Founding Date 1901 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||||
Locations | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU Wien, AT see more | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Braine L'alleud, BE Sao Paulo, BR Toronto, CA Shanghai, CN see more | Locations Ingelheim am Rhein, DE HQ Ouled Fayet, DZ Munro, AR Macquarie Park, AU Wien, AT Minsk, BY Bruxelles, BE see more | Locations Paris, FR HQ Hydra, DZ Buenos Aires, AR Macquarie Park, AU Melbourne, AU Virginia, AU Wien, AT see more | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations London, GB HQ Boumerdes, DZ Buenos Aires, AR Abbotsford, AU Wien, AT Wavre, BE Rio De Janeiro, BR see more | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Princeton, US HQ Mulgrave, AU Pinewood, AU Wien, AT Braine L'alleud, BE Bruxelles, BE São Paulo, BR see more | Locations Petah Tikva, IL HQ Villa Adelina, AR Macquarie Park, AU Minsk, BY Antwerpen, BE Sao Paulo, BR Dupnica, BG see more | |
Employees | Employees 94,3005% increase | Employees 18,726 | Employees 1,2338% increase | Employees 82,8784% decrease | Employees 75,883 | Employees 68,6292% decrease | Employees 25,200 | Employees 92,8152% decrease | Employees 34,100 | Employees 33,8928% decrease |
Valuation ($) | Valuation ($) 2.7 b | Valuation ($) 61.7 b | Valuation ($) N/A | Valuation ($) 141.1 b | Valuation ($) N/A | Valuation ($) 862.5 m | Valuation ($) 170.4 b | Valuation ($) 27.1 b | Valuation ($) 97.8 b | Valuation ($) 20.8 b |
Financial | ||||||||||
Revenue (est.) | Revenue (est.) $54.1b (FY, 2024) | Revenue (est.) ¥1t (FY, 2021) | Revenue (est.) €8.9b (FY, 2021) | Revenue (est.) €46.1b (FY, 2024) | Revenue (est.) $51.7b (FY, 2024) | Revenue (est.) £31.4b (FY, 2024) | Revenue (est.) $33.4b (FY, 2024) | Revenue (est.) €46.6b (FY, 2024) | Revenue (est.) $48.3b (FY, 2024) | Revenue (est.) $16.5b (FY, 2024) |
Cost of goods | Cost of goods $9b (FY, 2024) | Cost of goods ¥353.3b (FY, 2021) | Cost of goods €3b (FY, 2021) | Cost of goods €11.3b (FY, 2024) | Cost of goods $7.7b (FY, 2024) | Cost of goods £6.1b (FY, 2024) | Cost of goods $12.9b (FY, 2024) | Cost of goods €12b (FY, 2024) | Cost of goods $14b (FY, 2024) | Cost of goods $8.5b (FY, 2024) |
Gross profit | Gross profit $45.4b (FY, 2024) | Gross profit ¥691.6b (FY, 2021) | Gross profit €6b (FY, 2021) | Gross profit €38.9b (FY, 2024) | Gross profit $45.2b (FY, 2024) | Gross profit £25.9b (FY, 2024) | Gross profit $20.6b (FY, 2024) | Gross profit €35.8b (FY, 2024) | Gross profit $34.3b (FY, 2024) | Gross profit $8.1b (FY, 2024) |
Net income | Net income $7b (FY, 2024) | Net income ¥67b (FY, 2021) | Net income €2.2b (FY, 2021) | Net income €5.6b (FY, 2024) | Net income $11.9b (FY, 2024) | Net income £3b (FY, 2024) | Net income $4.1b (FY, 2024) | Net income (€2.5b) (FY, 2024) | Net income ($8.9b) (FY, 2024) | Net income ($2b) (FY, 2024) |
Operating ⚠ | ||||||||||
Countries | Countries 130 (FY, 2021) | Countries N/A | Countries N/A | Countries N/A | Countries N/A | Countries 92 (FY, 2021) | Countries 100 (FY, 2020) | Countries 83 (FY, 2021) | Countries N/A | Countries N/A |
Facilities | Facilities N/A | Facilities N/A | Facilities N/A | Facilities N/A | Facilities N/A | Facilities N/A | Facilities 180 (FY, 2020) | Facilities N/A | Facilities N/A | Facilities 90 (FY, 2019) |
Manufacturing Facilities | Manufacturing Facilities N/A | Manufacturing Facilities 13 (Jun, 2022) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 8 (FY, 2021) | Manufacturing Facilities N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 16 (FY, 2018) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 16 (FY, 2021) | Phase I Trials Products 20 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 9 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 20 (FY, 2021) | Phase I Trials Products (Oncology) N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 7 (FY, 2018) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 6 (FY, 2021) | Phase II Trials Products 5 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 12 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 15 (FY, 2021) | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 7 (FY, 2018) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products 11 (FY, 2021) | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 27 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 7 (FY, 2021) | Phase III Trials Products (Oncology) N/A |
Projects in R&D Pipeline | Projects in R&D Pipeline 177 (FY, 2021) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 91 (FY, 2019) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A |
Suppliers | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 68 k (FY, 2019) | Suppliers N/A | Suppliers 37.5 k (FY, 2021) | Suppliers N/A | Suppliers 93.8 k (FY, 2021) | Suppliers N/A | Suppliers N/A |
Trademark Applications | Trademark Applications N/A | Trademark Applications 46 (Jun, 2022) | Trademark Applications 1.1 k (Feb, 2024) | Trademark Applications N/A | Trademark Applications N/A | Trademark Applications N/A | Trademark Applications N/A | Trademark Applications N/A | Trademark Applications N/A | Trademark Applications N/A |
Trademarks | Trademarks N/A | Trademarks 112 (Jun, 2022) | Trademarks 5.2 k (Feb, 2024) | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks 1.5 k (FY, 2021) | Trademarks N/A | Trademarks N/A |
Funding | ||||||||||
Total funding raised | Total funding raised $ 1b | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 310m | Total funding raised $ 6.5m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 3.5b | Total funding raised $ 15.5m | Total funding raised $ 358m |
For sources of this data, please see the company profile
View Company Profiles
Daiichi Sankyo
HQ
Tokyo, JP
Employees
18,726
Daiichi Sankyo (第一三共株式会社) is a company specializing in the research, development, and manufacture of innovative pharmaceutical products.
View companyBoehringer Ingelheim
HQ
Ingelheim am Rhein, DE
Boehringer Ingelheim International is a pharmaceutical company specializing in animal health, human pharma, and biopharmaceutical contract manufacturing.
View companySanofi
HQ
Paris, FR
Employees
82,878↓ 4% decrease
Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
View companyNovartis
HQ
Basel, CH
Employees
75,883
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View company